Pharmacyclics (PCYC) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pharmacyclics (PCYC) Remains Rated Sector Perform at RBC, PT Raised to $145
February 19, 2015 9:04 AM ESTRBC Capital maintained a Sector Perform rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $145.00 (from $130.00). Comments follow Q4 results. Analyst Michael J. Yee thinks bulls are in control of the stock.
"We predict stock likely to keep trending up... More
Nomura Securities Upgrades Pharmacyclics (PCYC) to Buy
February 19, 2015 6:59 AM ESTNomura Securities upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $196.00 (from $195.00), saying the RESONATE-2 data is key to upside in 2015
Analyst M. Ian Somaiya commented, "Pharmacyclics management reaffirmed their 2015 US sales guidance of $1bn and more importantly confirmed results of... More
UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares
February 19, 2015 6:56 AM EST(Updated - February 19, 2015 8:59 AM EST)
Roth Capital cuts Pharmacyclics (Nasdaq: PCYC) from Buy to Neutral and moves its price target from $189 to $187 following FY14 results reported on Wednesday night.
After markets close, Pharmacyclics posted Q4 EPS of $0.96 on revs of $290... More
JPMorgan Downgrades Pharmacyclics (PCYC) to Neutral
February 19, 2015 6:55 AM ESTJPMorgan downgraded Pharmacyclics (NASDAQ: PCYC) from Overweight to Neutral with a price target of $173.00 (from $152.00).
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $170.21 yesterday.
... More